A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.

Date publication

octobre 2022

Journal

Frontiers in bioscience (Landmark edition)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CIANFERANI Sarah , Pr PIVOT Xavier , Dr DETAPPE Alexandre , Dr COLIAT Pierre

Tous les auteurs :
Deslignière E, Diemer H, Erb S, Coliat P, Pivot X, Detappe A, Hernandez-Alba O, Cianférani S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36336868

Résumé

Native mass spectrometry (nMS) approaches appear attractive to complement bottom-up strategies traditionally used in biopharmaceutical industries thanks to their quite straightforward and rapid workflows, especially through online hyphenation of non-denaturing liquid chromatography (LC) to nMS. The present work provides an overview of the state-of-the-art chromatographic tools available for the detailed characterization of monoclonal antibody (mAb) formats, exemplified on the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd).

Mots clés

antibody-drug conjugate (ADC), biotherapeutics, cation exchange chromatography (CEX), higher order structures, hydrophobic interaction chromatography (HIC), liquid chromatography (LC), native mass spectrometry (MS), size exclusion chromatography (SEC)

Référence

Front Biosci (Landmark Ed). 2022 10 26;27(10):290